Chief Business Officer · Janux Therapeutics, Inc. · Common Stock
Side
M
Value
$35K
Shares
3,333
Price
$10.59
Executed
Nov 14, 2025
Disclosed
Nov 14, 2025
Disclosure timeline0 days from execution to publication · legal deadline 2 business days
Nov 14 executedNov 14, 2025 disclosed
JANX · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Option exercise — administrative, little informational value
Relative size+1 / 25
$35K reported value · 3.9% of prior position
Filing timing0 / 15
Disclosed 0 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
Pre-arranged plan-10
Executed under a Rule 10b5-1 trading plan
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Meyer Andrew Hollman filed this Form 4 reporting a option exercise of JANX on Nov 14, 2025. It became public on Nov 14, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Chief Business Officer
Meyer Andrew Hollmancik:0001864159
Issuer
Janux Therapeutics, Inc.cik:0001817713
Revision history · 0
No field has changed since this record was first ingested.
